242 related articles for article (PubMed ID: 34922050)
1. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.
John T; Taylor A; Wang H; Eichinger C; Freeman C; Ahn MJ
Cancer Epidemiol; 2022 Feb; 76():102080. PubMed ID: 34922050
[TBL] [Abstract][Full Text] [Related]
2. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Tu HY; Ke EE; Yang JJ; Sun YL; Yan HH; Zheng MY; Bai XY; Wang Z; Su J; Chen ZH; Zhang XC; Dong ZY; Wu SP; Jiang BY; Chen HJ; Wang BC; Xu CR; Zhou Q; Mei P; Luo DL; Zhong WZ; Yang XN; Wu YL
Lung Cancer; 2017 Dec; 114():96-102. PubMed ID: 29173773
[TBL] [Abstract][Full Text] [Related]
5. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
7. Current management of uncommon EGFR mutations in non-small cell lung cancer.
Trinh JQ; Abughanimeh O
Curr Probl Cancer; 2024 Apr; 49():101064. PubMed ID: 38311523
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India.
Singh V; Nambirajan A; Malik PS; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Mohan A; Jain D
Lung Cancer; 2020 Nov; 149():53-60. PubMed ID: 32971387
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract][Full Text] [Related]
10. Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.
Pretelli G; Spagnolo CC; Ciappina G; Santarpia M; Pasello G
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240224
[TBL] [Abstract][Full Text] [Related]
11. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
12. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
13. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
Passaro A; Prelaj A; Bonanno L; Tiseo M; Tuzi A; Proto C; Chiari R; Rocco D; Genova C; Sini C; Cortinovis D; Pilotto S; Landi L; Bennati C; Camerini A; Toschi L; Putzu C; Cerea G; Spitaleri G; Cappuzzo F; de Marinis F
Clin Lung Cancer; 2019 Mar; 20(2):e186-e194. PubMed ID: 30563752
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
15. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
[TBL] [Abstract][Full Text] [Related]
16. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
[TBL] [Abstract][Full Text] [Related]
19. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
20. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
